Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
← catalyst calendarNCT06943755 · readout in 1,046 d
Sponsored by Exelixis (industry) · EXEL — their whole pipeline →.
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
440estimated
Sites
120
Countries
Australia, Austria, Belgium +12
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-21 | actual | When the study began enrolling |
| Primary completion | 2029-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Pancreatic Neuroendocrine Tumor (pNET)
- Extra-Pancreatic Neuroendocrine Tumor (epNET)
Interventions
- Drug: Zanzalintinib — also filed as XL092
- Drug: Everolimus — also filed as Afinitor
Primary outcome
what the primary-completion date above is the date OFProgression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)
measured Up to 48 months
Permalink · EXEL's whole pipeline · Catalyst calendar · Every registered study · What changed